Insights from 8 Analyst Ratings on Repligen
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Oct 01 2025
0mins
Should l Buy RGEN?
Source: Benzinga
Analyst Ratings Overview: Eight analysts have provided varied opinions on Repligen (RGEN), with recent ratings showing a mix of bullish and somewhat bullish sentiments, alongside a slight decrease in the average 12-month price target to $161.12.
Company Performance Insights: Repligen has demonstrated strong revenue growth of 14.81% over the past three months, although its return on equity and return on assets are below industry averages, indicating challenges in capital and asset utilization.
Debt Management: The company maintains a favorable debt-to-equity ratio of 0.33, suggesting a lower reliance on debt financing compared to industry peers, which may be viewed positively by investors.
Analyst Evaluation Process: Analysts assess stocks quarterly based on company performance, financial statements, and insider communications, providing ratings and forecasts that can guide investor decisions, albeit with potential for human error.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy RGEN?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on RGEN
Wall Street analysts forecast RGEN stock price to rise
12 Analyst Rating
9 Buy
3 Hold
0 Sell
Strong Buy
Current: 123.060
Low
165.00
Averages
189.00
High
207.00
Current: 123.060
Low
165.00
Averages
189.00
High
207.00
About RGEN
Repligen Corporation is a global life sciences company that develops and commercializes bioprocessing technologies and systems. Its focus areas are Filtration and Fluid Management, Chromatography, Process Analytics and Proteins. Its filtration products are used in process development and process scale (clinical and commercial) production. Its XCell ATF systems are used in upstream perfusion (continuous) and N-1 (intensified fed-batch or hybrid perfusion) cell culture processing. Its chromatography franchise includes several products used in downstream purification, development, manufacturing and quality control of biological drugs. Its process analytics products complement and support its filtration, chromatography and protein franchises. Its TangenX product portfolio includes flat sheet (FS) tangential flow filtration (TFF) cassettes used primarily in downstream and ultrafiltration processes. Its desktop portfolio includes MAVERICK and MAVEN, REBEL, and ZipChip.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Repligen Corporation Reports Strong Q4 2025 Earnings and 2026 Guidance
- Strong Financial Performance: Repligen reported Q4 2025 revenue of $198 million, an 18% year-over-year increase, with full-year revenue reaching $738 million and a 16% organic growth rate, reflecting robust performance in the bioprocessing market.
- 2026 Guidance: Management introduced revenue guidance for 2026 between $810 million and $840 million, representing 9% to 13% organic growth, despite a noted 2-point headwind from a gene therapy platform, indicating confidence in future prospects.
- Product Innovation and Market Expansion: The company launched new AVIPure resins and gained traction with the SoloVPE PLUS analytics platform, emphasizing successful cross-selling initiatives, with product line sales to key customers increasing 2.5 times since 2019, showcasing significant market penetration.
- Operational Efficiency Improvement: Management expects adjusted operating income for 2026 to be between $122 million and $130 million, with projected adjusted gross margins expanding to 53.6% to 54.1%, which will enhance the company's profitability in a competitive landscape.
See More
Repligen Q4 Earnings Exceed Expectations
- Earnings Highlights: Repligen reported a Q4 non-GAAP EPS of $0.49, beating expectations by $0.05, with revenue of $197.91 million reflecting an 18.1% year-over-year increase, surpassing market expectations by $5.68 million, indicating robust market performance and profitability.
- 2026 Financial Guidance: The company projects total revenue for 2026 to be between $810 million and $840 million, with a growth rate of 10% to 14%, and an organic growth forecast of 9% to 13%, reflecting confidence in future growth and optimistic market demand.
- Margin Expansion: Adjusted operating margin is expected to expand by 150 basis points to a range of 15.1% to 15.5% in 2026, which will further enhance the company's profitability and competitive position, supporting its long-term strategic objectives.
- Market Expectations Comparison: Although the projected EPS for 2026 is between $1.93 and $2.01, below the consensus estimate of $2.07, the company still demonstrates strong financial resilience and potential for sustained growth.
See More
Repligen Exceeds 2025 Revenue Expectations with Strong Growth
- Quarterly Revenue Growth: Repligen reported fourth-quarter revenue of $198 million, an 18% year-over-year increase with 14% organic growth, indicating strong momentum in orders and reinforcing the company's market position in bioprocessing technology.
- Impressive Annual Performance: The full-year 2025 revenue reached $738 million, a 16% increase compared to the previous year, surpassing the company's initial revenue and adjusted operating income guidance, reflecting the strong appeal of its differentiated product portfolio.
- Positive 2026 Outlook: The company anticipates 2026 revenue guidance between $810 million and $840 million, with growth rates of 10% to 14%, alongside expected adjusted operating margin expansion of 150 basis points at the midpoint, demonstrating confidence in future growth.
- Investment in APAC Market: In the fourth quarter, Repligen opened a new office in Singapore and expanded its footprint in Japan, aiming to enhance its market presence in the Asia-Pacific region to support future growth strategies.
See More
Repligen Scheduled to Announce Q4 Earnings on February 24
- Earnings Announcement Date: Repligen is set to announce its Q4 earnings on February 24 before market open, with a consensus EPS estimate of $0.44, indicating stable profitability year-over-year.
- Revenue Growth Expectations: The anticipated revenue for Q4 is $192.23 million, reflecting a 14.7% year-over-year increase, which underscores the company's ongoing growth and strong market demand in the biopharmaceutical sector.
- Performance Beat Record: Over the past two years, Repligen has exceeded EPS and revenue estimates 63% of the time, demonstrating reliability in financial performance and bolstering market confidence.
- Estimate Revision Dynamics: In the last three months, EPS estimates have seen two upward revisions and one downward revision, indicating analyst divergence regarding the company's future performance, which may influence investor decisions.
See More
Repligen Corporation to Report Q4 2025 Financial Results on February 24, 2026
- Earnings Release Schedule: Repligen Corporation will report its Q4 2025 financial results on February 24, 2026, with a press release expected before market open, providing investors with timely financial updates and business insights.
- Conference Call Details: The company will host a conference call at 8:30 a.m. ET, allowing domestic callers to dial toll-free (800) 715-9871 and international callers to use (646) 307-1963, facilitating investor engagement and detailed discussions on financial results.
- Webcast Access: Investors can access the conference call via a webcast on the company's Investor Relations section, ensuring global investors can receive real-time critical information, thereby enhancing transparency and communication.
- Company Overview: Repligen is a global life sciences company focused on developing and commercializing bioprocessing technologies that serve biopharmaceutical developers and contract development manufacturing organizations, showcasing its innovative capabilities and market impact in the biopharmaceutical sector.
See More
RGEN Stock 52-Week Highs and Lows Analysis
- Price Fluctuation Analysis: RGEN's 52-week low is $102.965 per share, while the high is $175.77, with the last trade at $139.66, indicating significant price movement within this range and reflecting market interest and investor sentiment changes.
- Technical Indicator Observation: The current price of $139.66 is below the 200-day moving average, suggesting potential downward pressure on the stock in the short term, prompting investors to monitor market dynamics for risk assessment.
- Market Sentiment Evaluation: Although the current stock price is positioned in the middle of the 52-week range, the significant gap from the high may affect investor confidence and willingness to buy, necessitating close attention to market reactions.
- Investment Strategy Recommendation: Investors considering RGEN stock should integrate technical analysis and market trends to evaluate its investment value at the current price level, thereby formulating a sound investment strategy.
See More
Repligen Corporation Reports Strong Q4 2025 Earnings and 2026 Guidance
- Strong Financial Performance: Repligen reported Q4 2025 revenue of $198 million, an 18% year-over-year increase, with full-year revenue reaching $738 million and a 16% organic growth rate, reflecting robust performance in the bioprocessing market.
- 2026 Guidance: Management introduced revenue guidance for 2026 between $810 million and $840 million, representing 9% to 13% organic growth, despite a noted 2-point headwind from a gene therapy platform, indicating confidence in future prospects.
- Product Innovation and Market Expansion: The company launched new AVIPure resins and gained traction with the SoloVPE PLUS analytics platform, emphasizing successful cross-selling initiatives, with product line sales to key customers increasing 2.5 times since 2019, showcasing significant market penetration.
- Operational Efficiency Improvement: Management expects adjusted operating income for 2026 to be between $122 million and $130 million, with projected adjusted gross margins expanding to 53.6% to 54.1%, which will enhance the company's profitability in a competitive landscape.
See More
Repligen Q4 Earnings Exceed Expectations
- Earnings Highlights: Repligen reported a Q4 non-GAAP EPS of $0.49, beating expectations by $0.05, with revenue of $197.91 million reflecting an 18.1% year-over-year increase, surpassing market expectations by $5.68 million, indicating robust market performance and profitability.
- 2026 Financial Guidance: The company projects total revenue for 2026 to be between $810 million and $840 million, with a growth rate of 10% to 14%, and an organic growth forecast of 9% to 13%, reflecting confidence in future growth and optimistic market demand.
- Margin Expansion: Adjusted operating margin is expected to expand by 150 basis points to a range of 15.1% to 15.5% in 2026, which will further enhance the company's profitability and competitive position, supporting its long-term strategic objectives.
- Market Expectations Comparison: Although the projected EPS for 2026 is between $1.93 and $2.01, below the consensus estimate of $2.07, the company still demonstrates strong financial resilience and potential for sustained growth.
See More
Repligen Exceeds 2025 Revenue Expectations with Strong Growth
- Quarterly Revenue Growth: Repligen reported fourth-quarter revenue of $198 million, an 18% year-over-year increase with 14% organic growth, indicating strong momentum in orders and reinforcing the company's market position in bioprocessing technology.
- Impressive Annual Performance: The full-year 2025 revenue reached $738 million, a 16% increase compared to the previous year, surpassing the company's initial revenue and adjusted operating income guidance, reflecting the strong appeal of its differentiated product portfolio.
- Positive 2026 Outlook: The company anticipates 2026 revenue guidance between $810 million and $840 million, with growth rates of 10% to 14%, alongside expected adjusted operating margin expansion of 150 basis points at the midpoint, demonstrating confidence in future growth.
- Investment in APAC Market: In the fourth quarter, Repligen opened a new office in Singapore and expanded its footprint in Japan, aiming to enhance its market presence in the Asia-Pacific region to support future growth strategies.
See More
Repligen Scheduled to Announce Q4 Earnings on February 24
- Earnings Announcement Date: Repligen is set to announce its Q4 earnings on February 24 before market open, with a consensus EPS estimate of $0.44, indicating stable profitability year-over-year.
- Revenue Growth Expectations: The anticipated revenue for Q4 is $192.23 million, reflecting a 14.7% year-over-year increase, which underscores the company's ongoing growth and strong market demand in the biopharmaceutical sector.
- Performance Beat Record: Over the past two years, Repligen has exceeded EPS and revenue estimates 63% of the time, demonstrating reliability in financial performance and bolstering market confidence.
- Estimate Revision Dynamics: In the last three months, EPS estimates have seen two upward revisions and one downward revision, indicating analyst divergence regarding the company's future performance, which may influence investor decisions.
See More
Repligen Corporation to Report Q4 2025 Financial Results on February 24, 2026
- Earnings Release Schedule: Repligen Corporation will report its Q4 2025 financial results on February 24, 2026, with a press release expected before market open, providing investors with timely financial updates and business insights.
- Conference Call Details: The company will host a conference call at 8:30 a.m. ET, allowing domestic callers to dial toll-free (800) 715-9871 and international callers to use (646) 307-1963, facilitating investor engagement and detailed discussions on financial results.
- Webcast Access: Investors can access the conference call via a webcast on the company's Investor Relations section, ensuring global investors can receive real-time critical information, thereby enhancing transparency and communication.
- Company Overview: Repligen is a global life sciences company focused on developing and commercializing bioprocessing technologies that serve biopharmaceutical developers and contract development manufacturing organizations, showcasing its innovative capabilities and market impact in the biopharmaceutical sector.
See More
RGEN Stock 52-Week Highs and Lows Analysis
- Price Fluctuation Analysis: RGEN's 52-week low is $102.965 per share, while the high is $175.77, with the last trade at $139.66, indicating significant price movement within this range and reflecting market interest and investor sentiment changes.
- Technical Indicator Observation: The current price of $139.66 is below the 200-day moving average, suggesting potential downward pressure on the stock in the short term, prompting investors to monitor market dynamics for risk assessment.
- Market Sentiment Evaluation: Although the current stock price is positioned in the middle of the 52-week range, the significant gap from the high may affect investor confidence and willingness to buy, necessitating close attention to market reactions.
- Investment Strategy Recommendation: Investors considering RGEN stock should integrate technical analysis and market trends to evaluate its investment value at the current price level, thereby formulating a sound investment strategy.
See More
